European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- |work| -

: Delayed-release tablets intended to resist gastric fluid and release the active substance in the intestinal tract.

Effervescent tablets and chewable tablets are exempt from friability testing due to their intended use.

Roche Friabilator (drum rotating at 25 RPM). Procedure: Dedust 10 tablets. Weigh exactly. Rotate for 100 revolutions (4 minutes). Dedust and reweigh. Acceptance criteria:

Understanding how to apply the monograph in practice is crucial for manufacturers. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Standard forms, with film-coated variants specified for thin polymeric layers.

| Test Category | Key Aspects & Acceptance Criteria | | :--- | :--- | | | Verifies that each tablet contains the correct amount of active substance. The test method depends on the substance's content. Uniformity of Content is used for low-dose tablets (< 2 mg or < 2% of total mass), while Uniformity of Mass (2.9.5) is used otherwise. If Uniformity of Content is performed, the mass test is not required. | | Dissolution/Disintegration | The Rule: A dissolution test is required for immediate-release solid dosage forms. The Exception: If a dissolution test is performed, a disintegration test is not required. The Method: For dissolution, one of the tests in general chapter 2.9.3 must be used (unless another is justified). For disintegration, the standard method (2.9.1) is used. | | Friability (2.9.7) & Crushing Strength (2.9.8) | These tests measure a tablet's physical durability and resistance to breakage, ensuring it can withstand the stress of manufacturing and handling. |

The European Pharmacopoeia (Ph. Eur.) is a publication that sets out the official standards for the quality, purity, and strength of medicines in Europe. One of the key monographs in the Ph. Eur. is the one for tablets, which is identified by the code "0478". In this article, we will provide an in-depth look at the Ph. Eur. monograph for tablets, its significance, and the requirements that manufacturers must meet to ensure the quality of their tablet products. : Delayed-release tablets intended to resist gastric fluid

[Granulation / Blending] ──> [In-Process Mechanical Testing] ──> [Microbiological & Divisibility Quality Checks]

Intended to be dissolved or dispersed in water before intake.

In the complex world of pharmaceutical manufacturing, consistency isn't just a goal—it's a legal requirement. For anyone operating within the 39 member states of the European Pharmacopoeia Convention European Pharmacopoeia (Ph. Eur.) Monograph 0478 Procedure: Dedust 10 tablets

Designed to change the rate, place, or time of drug release (e.g., prolonged or delayed release).

: Allowed up to 60 minutes (excluding film-coated, which are 30 minutes). Soluble/Dispersible : Must break down within 3 minutes . 2. Dissolution (General Chapter 2.9.3)

The European Pharmacopoeia is published by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a department of the Council of Europe. The Ph. Eur. is a reference work that contains a collection of monographs, general chapters, and reagents that define the quality standards for medicines. Its primary objective is to ensure the quality, safety, and efficacy of medicines available to patients in Europe.

Ph. Eur. 2.9.5 This is the "20 tablets weighed" test.

| Category | Key Characteristics | | :--- | :--- | | | Single layer or multi-layer tablets without a coating. The most basic category. | | Coated Tablets | Covered with a coating (e.g., sugar, film) to protect ingredients or improve swallowability. | | Effervescent Tablets | Contain acids and carbonates; release gas when dissolved in water. Intended to be dissolved before administration. | | Soluble Tablets | Designed to dissolve completely in water, forming a clear or slightly opalescent solution. | | Dispersible Tablets | Intended to be dispersed in water to form a homogeneous dispersion before administration. | | Orodispersible Tablets | Designed to disintegrate rapidly (typically within 3 minutes) when placed on the tongue, releasing the active substance in saliva. | | Gastro-resistant Tablets | Also known as enteric-coated tablets. Their coating resists stomach acid and releases the active substance in the intestine. | | Modified-release Tablets | Formulated to release the active substance at a specific rate, over an extended period, or at a specific location in the GI tract. | | Tablets for Use in the Mouth | A broad category including buccal and sublingual tablets, designed to be retained in the mouth. Note: The Ph. Eur. has redefined this category to be within the scope of the Oromucosal preparations monograph (1807). | | Oral Lyophilisates | Freeze-dried, single-dose preparations that rapidly disintegrate in the mouth. The monograph's definition of this category has been clarified as "solid single-dose preparations made by freeze-drying of a liquid or semi-solid preparation". |